{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:01:31Z","timestamp":1782540091088,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jcjo.2020.05.017","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T16:56:13Z","timestamp":1598028973000},"page":"373-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina"],"prefix":"10.1016","volume":"55","author":[{"given":"Andres","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5744-0539","authenticated-orcid":false,"given":"Swati","family":"Agarwal-Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2020.05.017_bib0001","first-page":"1162","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"368","author":"Hartnett","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0002","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.earlhumdev.2007.12.004","article-title":"UK retinopathy of prematurity guideline","volume":"84","author":"Wilkinson","year":"2008","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0003","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0004","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","article-title":"Final visual acuity results in the early treatment for retinopathy of prematurity study","volume":"128","author":"Good","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0005","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","article-title":"Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"14","author":"Law","year":"2010","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0007","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0008","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0009","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0011","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0012","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0013","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0014","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcjo.2017.09.028","article-title":"Late onset tractional fibrovascular proliferation post intravitreal bevacizumab following treatment of retinopathy of prematurity","volume":"53","author":"Agarwal-Sinha","year":"2018","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3061","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0016","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"123","author":"Toy","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0017","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/14767058.2012.712313","article-title":"Fluorescein angiography and retinal vascular development in premature infants","volume":"25","author":"Purcaro","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0019","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0021","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0022","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/bjo.38.7.397","article-title":"Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia","volume":"38","author":"Ashton","year":"1954","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0023","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0024","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0025","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.ophtha.2015.02.018","article-title":"Author reply: To PMID 25001158","volume":"122","author":"Lepore","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0026","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0028","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/IAE.0b013e31820d3f70","article-title":"Management of avascular peripheral retina in older prematurely born infants","volume":"31","author":"Ho","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0029","doi-asserted-by":"crossref","first-page":"e85760","DOI":"10.1371\/journal.pone.0085760","article-title":"Current clinical evidence on the effect of general anesthesia on neurodevelopment in children: an updated systematic review with meta-regression","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2020.05.017_bib0030","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/anae.12637","article-title":"General anaesthetics and the developing brain: an overview","volume":"69","author":"Sinner","year":"2014","journal-title":"Anaesthesia"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418220306785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418220306785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:23:42Z","timestamp":1762104222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418220306785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0008418220306785"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2020.05.017","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2020.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}